Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets

Tiago Carvalheiro1, Diane Gomes2, Ligia A. Pinto3, Luis Inês4,5,6, Ana Lopes1, Ana Henriques5, Susana Pedreiro1, António Martinho1, Hélder Trindade1, Howard A. Young7, José António Pereira da Silva4,5 and Artur Paiva1,2*

Abstract

Background: Systemic Lupus Erythematosus (SLE) is an auto-immune disease whose complex pathogenesis remains unraveled. Here we aim to explore the inflammatory ability of SLE patients’ sera upon peripheral blood (PB) monocyte subsets and myeloid dendritic cells (mDCs) obtained from healthy donors.

Methods: In this study we included 11 SLE patients with active disease (ASLE), 11 with inactive disease (ISLE) and 10 healthy controls (HC). PB from healthy donors was stimulated with patients’ sera, toll-like receptor (TLR) 4 ligand – lipopolysaccharide or both. The intracellular production of TNF-α was evaluated in classical, non-classical monocytes and mDCs, using flow cytometry. TNF-α mRNA expression was assessed in all these purified cells, after sera treatment.

Results: We found that sera of SLE patients did not change spontaneous TNF-α production by monocytes or dendritic cells. However, upon stimulation of TLR4, the presence of sera from ASLE patients, but not ISLE, significantly increased the intracellular expression of TNF-α in classical and non-classical monocytes. This ability was related to titers anti-double stranded DNA antibodies in the serum. High levels of anti-TNF-α in the patients’ sera were associated with increased TNF-α expression by co-cultured mDCs. No relationship was found with the levels of a wide variety of other pro-inflammatory cytokines. A slight increase of TNF-α mRNA expression was observed in these purified cells when they were cultured only in the presence of SLE serum.

Conclusions: Our data suggest that SLE sera induce an abnormal in vitro TLR4 response in classical and non-classical monocytes, reflected by a higher TNF-α intracellular expression. These effects may be operative in the pathogenesis of SLE.

Keywords: Systemic lupus erythematosus, Serum, Cytokines, Toll like receptor 4, Classical monocytes, Non-classical monocytes, Myeloid dendritic cells

Background

Systemic lupus erythematosus (SLE) is a systemic auto-immune disease characterized by heterogeneous clinical manifestations with varying degrees of severity and alternating phases of remission and flare. The primary pathological findings in SLE patients are inflammation, vasculitis, immune complex deposition, and vasculopathy [1–4]. The disease is characterized by the presence of a variety of autoantibodies against cell components and circulating proteins, which are associated with differing disease manifestations [5].

Monocytes are key players in both innate and adaptive immune responses since they can produce large amounts of soluble cytokines and are equipped with a large array of receptors proving them with the ability of recognizing lipids, dying cells, microorganisms and their derivatives. Given the plasticity of monocytes and their distinct role in inflammation, repair and healing processes [6, 7], according to the recommendations of Ziegler-Heitbrock et al. it is possible to subdivide human monocytes into three...
subsets on the basis of the expression of CD14 and the CD16 receptors. The classical monocytes show high CD14 expression but no CD16 (CD14+CD16−), the intermediate monocytes show a high level of CD14 together with low CD16 (CD14+CD16+), and the nonclassical monocytes express a low level of CD14 together with high CD16 (CD14+CD16++) [8]. Functionally, classical monocytes are professional phagocytes that ingest native low-density lipoprotein, generate reactive oxygen species and secret cytokines in response to lipopolysaccharide (LPS) [9]. In contrast, non-classical monocytes do not generate reactive oxygen species and are weak phagocytes, taking-up preferentially oxidized low-density lipoprotein. They secrete substantial amounts of pro-inflammatory cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-1β and CCL3) after toll-like receptor (TLR) - dependent activation by viruses and nucleic acids [9–11].

It is also well accepted that dendritic cells (DCs) represent a heterogeneous population of potent lineage-negative HLA-DR+ antigen-presenting cells [12]. It is possible to identify at least two subsets of circulating DCs on the blood [8]; the myeloid DC (mDC) subpopulation, strongly expressing HLA-DR and the myeloid-associated antigens CD11c and CD33 and the plasmacytoid DC (pDCs) subset, expressing high levels of both HLA-DR and CD123, without expressing myeloid associated antigens [13].

Abnormalities in monocytes and DCs from SLE patients have already been described [14–16] and an important role of DCs in SLE pathogenesis been advocated [17, 18]. It has been reported that sera of SLE patients can induce the production of IFN-α in normal plasmacytoid DCs [19, 20]. SLE sera have also been shown to induce the differentiation of normal monocytes into DCs [21], and to promote a B cell response [22]. This pro-inflammatory activity apparently requires the presence of circulating immune complexes in the sera [20]. However the ability of the soluble mediators presents in SLE patients’ serum to activate normal peripheral blood monocytes subsets and mDCs is not well established.

In this context, we have evaluated the ability of sera from SLE patients to induce the intracellular production of TNF-α by classical, non-classical monocytes and mDCs. We examined the effect of SLE sera in the presence and absence of TLR4 stimulation by LPS. Interestingly, SLE sera did not change the intracellular production of TNF-α in the absence of TLR4 stimulation. However, the stimulation with TLR4 ligand in the presence of sera from ASLE resulted in a higher intracellular production of TNF-α by classical and non-classical monocytes, than in the presence of sera obtained from healthy controls and ISLE.

Materials and methods

Patients

Twenty two patients with SLE, according to the 1997 American College of Rheumatology classification criteria [23] followed at the Lupus Clinic, Rheumatology Department of the University Hospital Center of Coimbra, were recruited and asked to provide a blood sample for this study. Disease activity was assessed at the time of blood collection, according to the SLE Disease Activity Index 2000 (SLEDAI 2 k) [23, 24]. SLE patients were divided into two groups, one with clinically active disease (ASLE) (SLEDAI 2 k ≥ 5; n = 11, 100 % female, median age 27: 19–52 year) and the other with clinically inactive disease (ISLE) (SLEDAI 2 k < 5; n = 11, 64 % female, median age 28: 19–45 year) [25]. Current medication details and additional routine laboratory parameters were collected from the patients' files (Table 1). Sera samples were stored at −20 °C until analysis.

Controls

The healthy control group (HC) comprised 10 healthy individuals (90.0 % female, median age 28.5: 25 – 35 year)

Table 1 Clinical findings in 22 patients with systemic lupus erythematosus (SLE)

|                        | ASLE (n = 11) | ISLE (n = 11) |
|------------------------|--------------|--------------|
| Mean SLEDAI scores     | 10.4 ± 4.1   | 1.5 ± 1.2    |
| Mean time since diagnosis | 6.6 ± 6.0    | 8.3 ± 4.9    |
| Lupus nephritis        | 45.5 %       | 54.5 %       |
| Neurolupus             | 0 %          | 18.2 %       |
| Lupus arthritis        | 72.7 %       | 63.6 %       |
| Hematological involvement | 100 %        | 90.9 %       |
| Lupus cutaneous involve | 72.7 %       | 72.7 %       |
| Severe Lupus           | 45.5 %       | 54.5 %       |
| Anti-dsDNA antibodies  |              |              |
| Negative               | 0 %          | 27.2 %       |
| Low positive           | 9.1 %        | 36.4 %       |
| Moderate positive      | 18.2 %       | 27.3 %       |
| High positive          | 72.7 %       | 9.1 %        |
| Treatment              |              |              |
| Hydroxychloroquine     | 90.9 %       | 90.9 %       |
| Immunosuppressants     | 54.5 %       | 36.4 %       |
| Steroids               | 90.9 %       | 18.2 %       |
| Low dose               | 40.0 %       | 100 %        |
| Moderate dose          | 30.0 %       | 0 %          |
| High dose              | 30.0 %       | 0 %          |

* Lupus severity in accordance with cumulative major organ involvement
* Anti-dsDNA antibodies: low positive (<20 IU); moderate positive (20–50 IU); high positive (>50 IU)
* azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, methotrexate, cyclophosphamide or rituximab
* Low dose, up to 10 mg/day; moderate dose, 10–30 mg/day; high dose, more than 30 mg/day
who provided blood samples for determination of serum cytokine levels. Five different healthy donors provided an additional blood samples (90 % female; median age 29: 25 – 33 years) collected in heparin anticoagulant tubes (6 mL of blood). These participants were required to complete a brief questionnaire regarding previous or current medical conditions and therapies. All were free from autoimmune disease, other active inflammatory conditions and medication with immunomodulatory drugs.

Ethical aspects
The study protocol was approved by the ethics committee of the University Hospital Center of Coimbra. All participants provided a signed informed consent prior to any study procedures and the principles of the Helsinki Declaration were fully respected.

Peripheral blood cultures with sera from SLE patients and HC with and without co-stimulation with TLR4 ligand - LPS
To assess the effect of SLE sera upon TNF-α production by normal peripheral blood monocyte subsets and mDCs, sera from 11 ASLE patients, 11 ISLE patients and 10 healthy individuals were used. The heparinized whole blood samples obtained from healthy donors were washed thrice with NaCl 0.9 % saline solution and resuspended in 0.25 mL; then samples were diluted (1:1) in RPMI-1640 medium (Life Technologies – Thermo Fisher Scientific; Carlsbad, C.A., USA), supplemented with 2 mM L-glutamine and antibiotic–antimycotic agent (Life Technologies – Thermo Fisher Scientific) in a total of 0.5 mL. Four different conditions were created: 1) adding 0.05 mL of sera from patients with SLE or HC; 2) adding 100 ng/mL of LPS from *Escherichia coli* (serotype 055:B5; Sigma) plus 0.05 mL of sera from patients with SLE or HC; 3) adding 100 ng/mL of LPS from *Escherichia coli* (as a positive control) and 4) an unstimulated condition (as the negative control). All experiments included the presence of 10 µg/mL of Brefeldin A (ref: B7651; Sigma, St. Louis, MO, USA) to prevent the release of cytokines from the cells. Samples were incubated for 6 h at 37 °C in a sterile environment with a 5 % CO₂ humid atmosphere.

Immunofluorescent staining
After the 6 h incubation period, samples were aliquoted in two different tubes (0.250 mL/tube) in order to analyse the intracellular production of TNF-α in classical and non-classical monocytes as well as in mDCs. For the identification of these populations, cells were stained with the following monoclonal antibody combination: anti-CD16 krome orange (clone: J.33; Beckman Coulter – Immunotech, Marseille, France), anti-CD33 phycoerythrin cyanine 5 tandem (clone: D3HL60.251; Beckman Coulter – Immunotech) anti-CD14 allophycocyanin (clone: RM052; Beckman Coulter – Immunotech) and anti-HLA-DR peridinin chlorophyll protein cyanine 5 (clone: L243; Becton and Dickinson (BD) Biosciences, San Jose, CA, USA). After gentle mixing, cells were incubated for 15 min at room temperature in the dark followed by an intracytoplasmatic permeabilization protocol with IntraPrep Permeabilization Reagent (Beckman Coulter – Immunotech). Cells were fixed and permeabilized according to the manufacturer's instructions. Thereafter, anti-TNF-α antibody (clone MAb11; BD Pharmingen, San Diego, CA, USA) was added and incubated for 15 min at room temperature in the dark. The cells were then washed twice with phosphate-buffered saline (Gibco BRL-life Technologies) and resuspended in 0.250 mL of this buffer.

Flow cytometry data acquisition and analysis
Data acquisition was performed in a FACSCanto II flow cytometer (BD Biosciences) with the FACSDiva software (BD Biosciences) using the EuroFlow instrument setup data acquisition standard operating procedures [26]. For each sample at least 250.000 events were acquired.

Data analysis for each variable was performed using the flow cytometry software Infinicyt 1.6 (Cytognos, Salamanca, Spain). The evaluation of TNF-α production was based on the frequency (%) of positive cells within each cell subset and their corresponding expression as determined by the mean fluorescence intensity (MFI), expressed as a relative logical scale.

Since CD16 expression is lost shortly after LPS stimulation, as also reported by others [27–30], thus precluding the identification of CD16+ monocyte subsets. On the other hand CD33 remains unchanged during LPS stimulation [30] and therefore CD33 was used as an alternative marker to CD16. Using a combination of anti-CD16 Pacific Blue (clone: 3G8; BD Pharmingen), anti-CD14 allophycocyanin, anti-HLA-DR peridinin chlorophyll protein cyanine 5, anti-CD33 phycoerythrin cyanine 7 tandem and anti-CD45 krome orange in unstimulated cells it is possible distinguish between non-classical and classical monocytes base on CD33 and CD14 combination (Fig. 1). mDCs were identified base on their CD33<sup>high</sup>/HLA-DR<sup>high</sup> expression with intermediate forward and side scatter between lymphocytes and monocytes (Fig. 1) [15, 30].

TNF-α relative gene expression analysis after sorting of classical, non-classical monocytes, and mDCs, after culture in the presence of SLE or HC sera
We set out to evaluate the direct effect of sera from patients with SLE upon TNF-α mRNA expression by monocytes subsets and dendritic cells from normal individuals in the absence of LPS. For this purpose, a heparinized peripheral blood sample from one healthy subject was washed thrice with NaCl 0.9 % saline solution and diluted 1:1 in RPMI-1640 medium supplemented with
2 mM L-glutamine and antibiotic–antimycotic agent. 0.05 mL of serum was added in a final volume of 0.5 mL: 3 from ASLE, 3 from ISLE and 3 from HC. Each sample was incubated in quadruplicate for 6 h, at 37 °C in a sterile environment under 5 % CO₂.

For the cell sorting of classical monocytes, non-classical monocytes and mDCs, cells from each sample were resuspended in a final volume of 1 mL per sample, and lysed with 10 mL of NH₄Cl solution (Sigma) to remove the red blood cells. After 20 min of incubation, samples were centrifuged (5 min, at 540 × g) and the cell pellet was stained with the following monoclonal antibodies combination: anti-CD45 Krome Orange, anti-HLA-DR fluorescein isothiocyanate (clone: Immu-357; Beckman Coulter – Immunotech), anti-CD14 peridinin chlorophyll protein – Cyanin 5.5 (clone:M5E2; BD Pharmingen), anti-CD33 phycoerythrin (clone:P67.6; BD Biosciences) and anti-CD123 allophycocyanin (clone: 9 F5; BD Pharmingen). Next, the cells were incubated for 20 min at room temperature in the dark, washed and resuspended in phosphate-buffered saline (Gibco BRL-life Technologies).

Cell-sorting and purification were performed in FACS-Aria II cell sorter (BD Biosciences) using the FACSDiva software (BD Biosciences). Classical monocytes were identified and sorted by HLA-DR⁺/CD14⁺/CD33high/CD14⁻/CD16−phenotype, non-classical monocytes were HLA-DRinter/CD33inter/CD14neg/CD123neg, and mDCs were defined as HLA-DRhigh/CD33high/CD14neg/CD123neg.

Sorted cell populations were then centrifuged for 5 min at 300 × g and the pellets were resuspended in 350 μL of RLT Lysis Buffer (Qiagen, Hilden, Germany). Total RNA extraction was performed with the RNeasy Micro kit (Qiagen) according to the supplier’s instructions. Total RNA was eluted in a 14 μl volume of RNase-free water. In order to quantify the amount of total RNA extracted and verify RNA integrity, samples were analyzed using a 6000 Nano Chip kit, in an Agilent 2100 bioanalyzer (Agilent Technologies, Walbronn, Germany) and 2100 expert software, according to the
manufacturer’s instructions. RNA was reverse transcribed with iScript™ Reverse Transcription Supermix for RTqPCR (Bio-Rad, Hercules, Calif., USA), according to the manufacturer’s instructions. Relative quantification of gene expression using real-time PCR was performed in the LightCycler 480 II (Roche Diagnostics, Rotkreuz, Switzerland). Real-time PCR reactions were carried out using 1 × QuantiTect SYBR Green PCR Master Mix (Qiagen), 1 × QuantiTect Primer Assay TRAF1 (QT00095732) (Qiagen) and 20 ng of cDNA sample, in a total volume of 10 μL. The reactions were performed using the following thermal profile: 15 min at 95 °C, and 50 cycles of 15 s at 94 °C, 30 s at 55 °C and 30 s at 72 °C. Melting point analysis was done to ensure amplification of the specific product. Real-time PCR results were analyzed with the LightCycler software (Roche Diagnostics). GeNorm Reference Gene Selection kit (PrimerDesign Ltd., Southampton, England) in conjunction with the geNorm software (PrimerDesign Ltd.) were used to select the reference genes to normalize data. The reference genes used for gene expression analysis of classical, non-classical monocytes and mDC were the beta-2-microglobulin (B2M) (QT00088935) and the ubiquitin-c (UBC) (QT00234430). The normalized TNF-α gene expression were calculated using the delta-Ct method [31].

Serum cytokine quantitation
Measurements of IL-17F, IL-17A, IL1-7E, IL-10, IL-12p70, IL-13, IL-15, IL-22, IL-21, IL-23, IFN-γ and TNF-α were performed in all serum samples by Luminex xMAP using the MILLIPLEX MAP Human TH17 Magnetic Bead Panel (EMD Millipore, Billerica, MA, USA). The serum cytokine levels were determined by comparison with a standard curve obtained using the corresponding recombinant human cytokines.

Statistical analyses
Results were expressed as median/mean and range/interquartile range. Statistical evaluation of data was performed through non-parametric tests: The χ² and Fisher’s exact tests were used to evaluate the significance of associations between categorical variables. Continuous variables were compared by Kruskal-Wallis test and Mann–Whitney U test. A Spearman’s rank correlation was applied to assess the association between different parameters. The statistical analyses were performed using Statistical Package for Social Sciences IBM SPSS 20 (IBM, Armonk, NY, USA) and Graphpad Prism version 5 (GraphPad Software, San Diego, CA, USA). Differences were considered statistically significant when the p value was less than 0.05.

Results
Higher TNF-α intracellular expression in classical and non-classical peripheral blood monocytes, after TLR4 ligand stimulation in the presence of sera from SLE patients with active disease
In the absence of LPS, the production of TNF-α by the various monocyte subsets or mDCs was not significantly affected by the addition of sera from patients with active or inactive SLE as compared to sera from HCs. The frequency of these cells producing TNF-α was consistently below 5 %.

In the presence of the TLR4 ligand – LPS, co-culture with sera from patients with ASLE resulted in a higher intracellular expression of TNF-α (MFI) in classical and non-classical monocytes, in comparison to cells cultured with sera from HCs. Sera from patients with ISLE did not reveal differences between ASLE or HC. None of the SLE sera changed the TNF-α expression in mDCs co-treated with sera from the different groups (Fig. 2a). No differences were observed in the frequency of classical, non-classical monocytes or mDCs expressing TNF-α in the presence of sera from SLE patients when compared to HC sera (Table 2).

Sera of SLE patients with moderate to high positive levels of anti-dsDNA antibodies demonstrated an increased ability to induce TNF-α expression in classical and non-classical monocytes, co-stimulated with TLR4 ligand
SLE patients were categorized according to the serum levels of anti-dsDNA antibodies into negative-low positive (<20 IU) and moderate-high positive (>20 IU) (Table 1). Data analysis demonstrated that classical monocytes exposed to sera from patients with moderate-high positive anti-dsDNA antibodies presented a higher TNF-α expression than those exposed to sera from HC (Fig. 2b). Non-classical monocytes followed a similar trend but without reaching statistical significance (Fig. 2b). As before, no differences were demonstrated for TNF-α expression in mDCs (Fig. 2b).

High TNF-α levels in the serum of SLE donors is associated with higher intracellular expression of TNF-α in mDCs but not with peripheral blood monocytes
We next investigated the relationship between TNF-α production in monocytes subsets and mDCs and the levels of IL-17F, IL-17A, IL-17E, IL-10, IL-12p70, IL-13, IL-15, IL-22, IL-21, IL-23, IFN-γ and TNF-α in the serum added to the cultures. Our data revealed a positive correlation between the levels of TNF-α in the sera of SLE patients and the intracellular TNF-α expression in mDCs (Fig. 3). These levels were not correlated with intracellular TNF-α expression in peripheral blood monocytes. No significant correlations was found between the levels of TNF-α in the sera from HCs and
intracellular TNF-α expression in either mDCs ($p = 0.535$) or monocyte subsets.

The others cytokines levels did not correlate with the intracellular expression of TNF-α either in cultured mDCs or monocyte subsets. Additionally, no differences were found in the cytokines levels between the three groups of participants (Table 3).

**TNF-α mRNA gene expression in sorted monocytes subsets and mDCs in the presence of SLE patient’s serum without LPS co-stimulation**

Since the presence of SLE sera alone did not demonstrated the ability to shift the TNF-α intracellular expression in monocytes subsets and mDCs as measured by flow cytometry, we next used qRT-PCR to measure the TNF-α mRNA expression in these purified cells after treatment with SLE or HC sera, in the absence of LPS. For this analysis, we selected 6 SLE sera (3 ASLE patients and 3 ISLE patients) and 3 HC sera. Only a trend for a higher TNF-α mRNA expression in the presence of SLE sera versus HC sera in both classical and non-classical monocytes was observed (Fig. 4), although no statically significant differences were observed.

**Discussion**

SLE is a chronic autoimmune disorder associated with a large number of immunological abnormalities, which includes phenotypic and functional alterations in monocytes and DCs [14, 15, 32, 33]. These cell types have an increasingly recognized role in this complex disease. Soluble mediators present in SLE patient’s sera are able to perpetuate the cellular activation in this disease [20, 34, 35], however their effects on monocyte subsets (classical and non-classical monocytes), as well as mDCs are poorly understood.

The production of pro-inflammatory cytokines, such as TNF-α, can be directly stimulated by signaling immunoglobulin receptors, complement receptors or through several other cellular receptors, including pattern recognition receptors as TLRs [36]. The TNF-α intracellular expression in classical, non-classical monocytes and mDCs remained unchanged when these cells are exposed to sera from ISLE, ASLE or HCs. This may be due to the absence of sufficient amounts of primary TNF-α production activators in these sera. However, it is also possible that the expression of inhibitory Fc gamma receptors (FcγR), particularly FcγRIIB, is stimulated in these cells which may bind IgG immune complexes without triggering activation but preventing self-responses [37].

On other hand, in the presence of TLR4 ligand, classical and non-classical monocytes co-treated with sera from ALSE exhibit a higher production of TNF-α when compared to cells exposed to sera from HCs. Our data suggests that TLR4 activation in the presence of ASLE

Table 2 Frequency of classical, non-classical monocytes and mDCs producing TNF-α

|                | Classical monocytes | Non-classical monocytes | mDCs       |
|----------------|--------------------|-------------------------|------------|
| Basal          | 2.08 (1.27–3.19)   | 4.78 (3.99–5.12)        | 5.67 (2.94–7.79) |
| TLR4 ligand    | 95.81 (93.92–96.46)| 84.67 (49.64–99.323)   | 65.66 (61.98–78.30) |
| HC sera + TLR4 ligand | 95.80 (93.40–97.55) | 95.69 (82.25–99.323) | 64.04 (35.68–77.44) |
| ISLE sera + TLR4 ligand | 95.59 (93.88–98.51) | 96.02 (81.13–98.98) | 42.51 (26.03–77.20) |
| ASLE sera + TLR4 ligand | 97.01 (92.53–98.96) | 93.33 (72.85–99.35) | 41.03 (26.35–72.9) |

Results expressed in percentage (%) as median (minimum-maximum)
sera results in an aberrant response by classical and non-classical monocytes. These results are in line with the findings of Leadbetter et al. that reported an aberrant B-cell response mediated by IgG complexes and TLR4 activation in their mice experiments [38].

In order to better define which serum components could be implicated in the activation of monocytes, we explored the relationship between this activations and the serum levels of anti-dsDNA antibodies and cytokines. Remarkably, moderate-high levels of anti-dsDNA were associated with more intense activation of TNF-α production by classical and non-classical monocytes.

![Fig. 3](image)

Correlation between SLE sera TNF-α levels and TNF-α intracellular expression after TLR4 co-stimulation with different sera. Statistical significant differences were considered when \( p < 0.05 \). The correlations were assessed by the Spearman’s rank correlation.

| Table 3 Cytokine levels obtained in the 22 SLE patients and 10 healthy individuals |
|---------------------------------------------------------------|
| **HC n = 10** | **SLE n = 11** | **ASLE n = 11** | **P value significance** |
|----------------|----------------|----------------|------------------------|
| **IL-17A**     | Cytokine level (pg/mL) | 0.0 (0.0–0.0): 0.00 | 0.0 (0.0–113.40): 12.69 | 0.0 (0.0–62.04): 9.28 | ns |
| % of samples detected (n) | 0 % (n = 0) | 18.2 % (n = 2) | 27.3 % (n = 3) | ns |
| **IL-17E**     | Cytokine level (pg/mL) | 0.0 (0.0–286.21): 81.27 | 0.0 (0.0–1364.68): 159.38 | 0.0 (0.0–57.10): 5.19 | ns |
| % of samples detected (n) | 30 % (n = 3) | 18.2 % (n = 2) | 9.1 % (n = 1) | ns |
| **IL-17F**     | Cytokine level (pg/mL) | 0.0 (0.0–14.49): 3.93 | 0.0 (0.0–158.44): 19.10 | 0.0 (0.0–57.10): 5.19 | ns |
| % of samples detected (n) | 30 % (n = 3) | 27.3 % (n = 3) | 9.1 % (n = 1) | ns |
| **IL-12p70**   | Cytokine level (pg/mL) | 0.0 (0.0–46.87): 6.98 | 0.06 (0.0–60.76): 8.05 | 0.0 (0.0–85.52): 8.85 | ns |
| % of samples detected (n) | 30 % (n = 3) | 54.5 % (n = 6) | 36.4 % (n = 4) | ns |
| **IL-23**      | Cytokine level (pg/mL) | 0.0 (0.0–1134.54): 276.46 | 0.0 (0.0–1122.86): 1216.17 | 0.0 (0.0–2547.96): 258.94 | ns |
| % of samples detected (n) | 30 % (n = 3) | 18.2 % (n = 2) | 18.2 % (n = 2) | ns |
| **TNF-α**      | Cytokine level (pg/mL) | 7.68 (6.25–33.50): 12.38 | 13.57 (4.30–26.73): 13.66 | 14.51 (1.01–27.90): 16.47 | ns |
| % of samples detected (n) | 100 % (n = 10) | 100 % (n = 11) | 100 % (n = 11) | ns |
| **IFN-γ**      | Cytokine level (pg/mL) | 0.0 (0.0–8.96): 2.95 | 0.0 (0.0–167.11): 21.90 | 2.77 (0.0–79.40): 12.36 | ns |
| % of samples detected (n) | 40 % (n = 4) | 27.3 % (n = 3) | 63.6 % (n = 7) | ns |
| **IL-15**      | Cytokine level (pg/mL) | 0.0 (0.0–0.0): 0.0 | 0.0 (0.0–7.45): 1.41 | 0.0 (0.0–0.0): 0.0 | ns |
| % of samples detected (n) | 0 % (n = 0) | 18.2 % (n = 2) | 0 % (n = 0) | ns |
| **IL-10**      | Cytokine level (pg/mL) | 0.0 (0.0–0.0): 0.0 | 0.0 (0.0–6.58): 0.99 | 0.0 (0.0–5.36): 0.89 | ns |
| % of samples detected (n) | 0 % (n = 0) | 100 % (n = 11) | 100 % (n = 11) | ns |
| **IL-22**      | Cytokine level (pg/mL) | 0.0 (0.0–100.8): 18.77 | 0.0 (0.0–598.67): 64.06 | 0.0 (0.0–1598.5): 14.53 | ns |
| % of samples detected (n) | 30 % (n = 3) | 18.2 % (n = 2) | 9.1 % (n = 1) | ns |
| **IL-21**      | Cytokine level (pg/mL) | 0.0 (0.0–5.61): 0.80 | 0.0 (0.0–105.58): 12.13 | 0.0 (0.0–24.07): 2.68 | ns |
| % of samples detected (n) | 10 % (n = 1) | 18.2 % (n = 2) | 18.2 % (n = 2) | ns |
| **IL-13**      | Cytokine level (pg/mL) | 0.0 (0.0–0.0): 0.0 | 0.0 (0.0–56.44): 6.76 | 0.0 (0.0–0.0): 0.0 | ns |
| % of samples detected (n) | 0 % (n = 0) | 18.8 % (n = 2) | 0 % (n = 0) | ns |

Results expressed in pg/mL as median (minimum-maximum): mean % and (n =) represent the percentage (number of cases) of samples detected

\( p \) values were calculated by Kruskal-Wallis test and Mann–Whitney U test for continuous variables, and \( \chi^2 \) and Fisher’s exact tests were used to measure associations between categorical variables. ns: non-significant
ability to activate FcγR and TLRs, leads to increased production of TNF-α [20, 39]. This is supported by the evidence that cross-linking between IgGs to FcγRs triggers a wide variety of cellular functions, including release of inflammatory mediators, like cytokines, chemokines and reactive oxygen species [40, 41].

mDCs was not sensitive to the effects of sera of these diverse origins upon TNF-α expression, both in the absence and in the presence of LPS. This suggests that this subpopulation of DCs is less sensitive to a peripheral inflammatory environment, probably due to the fact that the majority of PB mDCs have an immature phenotype [14, 15]. In fact, the different pattern of TNF-α expression observed in classical monocytes, non-classical monocytes and mDCs can also be related with the differential expression of FcγRs. Classical monocytes constitutively express CD64 (FcγRI), a high affinity receptor, while non-classical monocytes express CD16 (FcγRIII), a low affinity receptor, and mDCs express low levels of CD32 (FcγRII) an intermediate affinity receptor [42–44].

We also explored the relationship between TNF-α expression and the levels of a large array of cytokines in the serum added to the cultures. Interestingly, we observed a positive correlation between TNF-α sera levels and TNF-α intracellular expression in mDC co-stimulated with TLR4 ligand in the presence of SLE sera. This finding is in line with the ability of soluble TNF-α induces mDCs maturation as well as TNF-α production [45, 46].

Finally, we analyzed whether SLE sera in the absence of TLR4 ligand, could result in alterations of TNF-α mRNA expression in classical, non-classical monocytes and mDCs. A slight, non-significant increase in the TNF-α mRNA expression was observed in both monocyte subsets in the presence of LPS. This effect may be partially explained by circulating auto-antibodies since the high levels of anti-dsDNA antibodies are associated with an enhanced TNF-α intracellular expression. This supports the concept that the presence of the immune-complexes is an important factor in cell activation and in the maintenance of chronic inflammation in SLE.

**Abbreviations**
ASLE: Systemic lupus erythematosus patients in active disease; DC: Dendritic cell; dsDNA: Double stranded DNA; FcγR: Fc gamma receptor; IFN: Interferon; IL: Interleukin; mDC: Myeloid dendritic cell; SLE: Systemic lupus erythematosus; SLEDAI: Systemic lupus erythematosus disease activity index 2000; TLR: Toll-like receptor; TNF-α: Tumor necrosis factor α.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
TC carried the analysis and interpretation of data, the statistical analysis and drafted the manuscript; DM performed cell cultures and flow cytometry assays; LAP and HAY determined the sera cytokines levels; LI and JAPS participated in the molecular studies; AH has been involved in manuscript revising; SP performed the cell sorting; HT, JAPS and AP contributed to conception and designed the study protocol and given final approval of the version to be published. All authors read and approved the final manuscript.

**Acknowledgments**
This work was partially supported by research grant from the Portuguese Society of Rheumatology (SPR): “Bolsa de Investigação na área das Doenças Reumáticas Inflamatórias – Bolsa SPR/MSD 2014” and by the Intramural Research Program of the NIH, National Cancer Institute.

**Author details**
1Blood and Transplantation Center of Coimbra, Portuguese Institute of Blood and Transplantation, Quinta da Vinha Moura, São Martinho do Bispo, 3041-861 Coimbra, Portugal. 2College of Health Technology of Coimbra, Rua 5 de Outubro, São Martinho do Bispo, 3046-854 Coimbra, Portugal. 3HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Building 469, 21702 Frederick, MD, USA. 4Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Praca Prof. Mota Pinto, 3000-075 Coimbra, Portugal. 5Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal. 6School of Health Sciences, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal. 7Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute at Frederick, Building 560, 21702-1201 Frederick, MD, USA.
3.7. The paradigm and implications for in vivo immunoregulation.

91. N-Ekdahl K, Nilsson B. Immune complexes in vivo. J Rheumatol. 1999;26:294–9.

36. Lacy P, Stow JL. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood. 2011;118:1665–70.

23. Bacchetta J, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: A disease activity index for lupus patients. The Committee on prognostic studies in SLE. Arthritis Rheum. 1992;35:630–40.

24. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91.

25. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19:685–708.

26. Kajina T, Flores-Montejo J, van der Velden VH, Martin-Ayuso M, Bottcher S, Rietema M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986–2010.

27. Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus and rheumatoid arthritis. Blood. 2007;6:450–6.

28. Griffiths B, Schefold JC, Zuckermann-Becker H, Volk HD, Meisel C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care. 2009;13:R119.

29. Piccoza M, Battistini L, Borsellino G. Mononuclear phagocytes and marker modulation: when CD16 disappears, CD38 takes the stage. Blood. 2013;122:456–7.

30. Paulhammer C, Schefold JC, Zuckermann-Becker H, Volk HD, Meisel C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care. 2009;13:R119.

31. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Immunol Rev. 2010;236:70–92.

32. Li T, Chen D, Chen Y, Huang X, Zhao Y, Xie Y, et al. Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatol Int. 2012;32:2863–9.

33. Sato Y, Miyata M, Sato Y, Nishimaki T, Kochi H, Kaukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J Rheumatol. 1999;26:294–301.

34. Ronnelid J, Tejde A, Mathsson L, Nilsson-Edahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2003;62:37–42.

35. Lacy P, Stow JL. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood. 2011;118:1665–70.

36. Gravallese EP, Boccia B, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 1998;12:231–48.

37. Berden JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Rheum. 2011;63:3067–77.

38. Geissner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Rev Immunol. 2002;20:211–41.

39. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz). 2011;59:35–44.

40. Sato Y, Miyata M, Sato Y, Nishimaki T, Kochi H, Kaukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J Rheumatol. 1999;26:294–301.

41. Nielsen CT, Ostergaard O, Stener L, Iversen LV, Truedsson L, Gullstrand B, et al. Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2002;61:279–85.

42. Hansen J, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2007;6(6):450–5.

43. Sato Y, Miyata M, Sato Y, Nishimaki T, Kochi H, Kaukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J Rheumatol. 1999;26:294–301.

44. Almeida J, Bueno C, Alguero MC, Sanchez ML, de Santiago M, Escribano L, et al. Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatol Int. 2012;32:2863–9.

45. Sule S, Rosen A, Petri M, Alpert E, Andrade F. Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells. PLoS One. 2011;6:e17495.

46. Crispin JC, Alcocer-Varela J. The role myeloid dendritic cells play in the resolution of inflammation. Nat Rev Immunol. 2010;10:427–39.

47. Li T, Lee PF, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz). 2011;59:35–44.

48. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Immunol Rev. 2010;236:70–92.

49. Li T, Chen D, Chen Y, Huang X, Zhao Y, Xie Y, et al. Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatol Int. 2012;32:2863–9.

50. Sato Y, Miyata M, Sato Y, Nishimaki T, Kochi H, Kaukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J Rheumatol. 1999;26:294–301.

51. Ronnelid J, Tejde A, Mathsson L, Nilsson-Edahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2003;62:37–42.

52. Lacy P, Stow JL. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood. 2011;118:1665–70.

53. Gravallese EP, Boccia B, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 1998;12:231–48.

54. Nielsen CT, Ostergaard O, Johnsen C, Jacobsen S, Heegaard NH. Distinct requirements for IRAK1/4 kinase activity across human cell types. J Immunol. 2011;186:1279–87.

55. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669–92.

56. Wong KL, Yeap WH, Tai JI, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res. 2012;51:341–57.

57. Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus and rheumatoid arthritis. Blood. 2007;6:450–6.